BioLife Solutions of Bothell, whose products preserve stored cells, tissues and organs for life-science applications, said it will start trading Wednesday on the Nasdaq Capital Market, NASDAQ’s market for small-cap companies.
The company, previously traded over the counter, said in a regulatory filing it has completed the sale of $15.4 million in stock and warrants and erased $14.3 million in debt by converting it to equity on similar terms.
BioLife last month reported 2013 sales of $8.5 million, up 58 percent from the prior year, and a net loss of $1.1 million, down from $1.7 million.
The company said it will retain its current ticker symbol, BLFS. The securities sale and debt-to-equity conversion increased BioLife’s outstanding shares to 12 million, according to president and CEO Mike Rice, yielding a market capitalization of nearly $50 million at Tuesday’s closing price of $3.85.
- On his birthday, Russell Wilson gives Seattle Seahawks perhaps his greatest game to beat Pittsburgh Steelers
- Seahawks 39, Steelers 30: What the national media are saying about Russell Wilson and Seattle's turnaround
- Update: Seahawks' Jimmy Graham suffers right knee injury vs. Steelers, will miss rest of season
- Seattle Seahawks’ swagger, hopes for playoffs are back after they slam door on Pittsburgh Steelers
- Suspected burglar dies after getting stuck in chimney